Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16427605 | 1.00 | KMT2A (0.53) | KMT2AMAPK1GRM5ALDH1A1HPGD | |
| SCHEMBL16426901 | 0.86 | SMN1; SMN2 (0.40) | KMT2AALDH1A1HSD11B1MAPTHSD17B2 | |
| SCHEMBL16426900 | 0.86 | SMN1; SMN2 (0.40) | KMT2AALDH1A1HSD11B1MAPTHSD17B2 | |
| SCHEMBL19499084 | 0.86 | SMN1; SMN2 (0.40) | KMT2AALDH1A1HSD11B1MAPTHSD17B2 | |
| SCHEMBL12414687 | 0.81 | KMT2A (0.64) | KMT2AMAPK1GRM5ALDH1A1HPGD | |
| SCHEMBL14067407 | 0.80 | KMT2A (0.59) | KMT2AMAPK1GRM5ALDH1A1HPGD | |
| SCHEMBL8327722 | 0.78 | KMT2A (0.61) | KMT2AMAPK1GRM5ALDH1A1HPGD | |
| SCHEMBL524061 | 0.78 | KMT2A (0.61) | KMT2AMAPK1GRM5ALDH1A1HPGD | |
| SCHEMBL4716526 | 0.78 | KMT2A (0.65) | KMT2AMAPK1GRM5ALDH1A1HPGD | |
| SCHEMBL8331851 | 0.78 | KMT2A (0.61) | KMT2AMAPK1GRM5ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3027601-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038488-A1 | SYK INHIBITORS | SYK, BTK, LYN | KMT2A 850/4885MAPK1 690/4885GRM5 2866/4885 |
| US-20160368918-A1 | SYK INHIBITORS | SYK, BTK, LYN | KMT2A 930/4885MAPK1 669/4885GRM5 2932/4885 |
| US-10005774-B2 | Syk inhibitors | SYK, BTK, LYN | KMT2A 930/4885MAPK1 669/4885GRM5 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.